Circulating concentrations of insulin-like growth factor-I and risk of breast cancer
- PMID: 9593409
- DOI: 10.1016/S0140-6736(97)10384-1
Circulating concentrations of insulin-like growth factor-I and risk of breast cancer
Abstract
Background: Insulin-like growth factor (IGF)-I, a mitogenic and antiapoptotic peptide, can affect the proliferation of breast epithelial cells, and is thought to have a role in breast cancer. We hypothesised that high circulating IGF-I concentrations would be associated with an increased risk of breast cancer.
Methods: We carried out a nested case-control study within the prospective Nurses' Health Study cohort. Plasma concentrations of IGF-I and IGF binding protein 3 (IGFBP-3) were measured in blood samples collected in 1989-90. We identified 397 women who had a diagnosis of breast cancer after this date and 620 age-matched controls. IGF-I concentrations were compared by logistic regression with adjustment for other breast-cancer risk factors.
Findings: There was no association between IGF-I concentrations and breast-cancer risk among the whole study group. In postmenopausal women there was no association between IGF-I concentrations and breast-cancer risk (top vs bottom quintile of IGF-I, relative risk 0.85 [95% CI 0.53-1.39]). The relative risk of breast cancer among premenopausal women by IGF-I concentration (top vs bottom tertile) was 2.33 (1.06-5.16; p for trend 0.08). Among premenopausal women less than 50 years old at the time of blood collection, the relative risk was 4.58 (1.75-12.0; p for trend 0.02). After further adjustment for plasma IGFBP-3 concentrations these relative risks were 2.88 and 7.28, respectively.
Interpretation: A positive relation between circulating IGF-I concentration and risk of breast cancer was found among premenopausal but not postmenopausal women. Plasma IGF-I concentrations may be useful in the identification of women at high risk of breast cancer and in the development of risk reduction strategies. Additional larger studies of this association among premenopausal women are needed to provide more precise estimates of effect.
Comment in
-
Insulin-like growth factor-I and new opportunities for cancer prevention.Lancet. 1998 May 9;351(9113):1373-5. doi: 10.1016/S0140-6736(05)79438-1. Lancet. 1998. PMID: 9593403 No abstract available.
-
Insulin-like growth factor-I and risk of breast cancer.Lancet. 1998 Aug 8;352(9126):488-9. doi: 10.1016/s0140-6736(05)79226-6. Lancet. 1998. PMID: 9708782 No abstract available.
-
Insulin-like growth factor-I and risk of breast cancer.Lancet. 1998 Aug 8;352(9126):489. doi: 10.1016/s0140-6736(05)79227-8. Lancet. 1998. PMID: 9708783 No abstract available.
-
Insulin-like growth factor-I and risk of breast cancer.Lancet. 1998 Aug 8;352(9126):489-90. doi: 10.1016/s0140-6736(05)79229-1. Lancet. 1998. PMID: 9708784 No abstract available.
-
Insulin-like growth factor-I and risk of breast cancer.Lancet. 1998 Aug 8;352(9126):490. doi: 10.1016/s0140-6736(05)79230-8. Lancet. 1998. PMID: 9708785 No abstract available.
Similar articles
-
Circulating levels of insulin-like growth factors, their binding proteins, and breast cancer risk.Cancer Epidemiol Biomarkers Prev. 2005 Mar;14(3):699-704. doi: 10.1158/1055-9965.EPI-04-0561. Cancer Epidemiol Biomarkers Prev. 2005. PMID: 15767352
-
Insulin-like growth factor-I, its binding proteins (IGFBP-1 and IGFBP-3), and growth hormone and breast cancer risk in The Nurses Health Study II.Endocr Relat Cancer. 2006 Jun;13(2):583-92. doi: 10.1677/erc.1.01149. Endocr Relat Cancer. 2006. PMID: 16728584
-
Insulin-like growth factor I (IGF-I), IGF-binding proteins, and breast cancer.Cancer Epidemiol Biomarkers Prev. 2002 Dec;11(12):1566-73. Cancer Epidemiol Biomarkers Prev. 2002. PMID: 12496045
-
Insulin-like growth factor-I and binding protein-3 and risk of cancer.Horm Res. 1999;51 Suppl 3:34-41. doi: 10.1159/000053160. Horm Res. 1999. PMID: 10592442 Review.
-
Insulin-like growth factor (IGF)-I and IGF-binding protein 3 and the risk of premenopausal breast cancer: a meta-analysis of literature.Int J Cancer. 2004 Aug 20;111(2):293-7. doi: 10.1002/ijc.20253. Int J Cancer. 2004. PMID: 15197785
Cited by
-
Correlation between insulin‑like growth factor binding protein 3 and metastasis‑associated gene 1 protein in esophageal squamous cell carcinoma.Mol Med Rep. 2016 May;13(5):4143-50. doi: 10.3892/mmr.2016.5046. Epub 2016 Mar 28. Mol Med Rep. 2016. PMID: 27035126 Free PMC article.
-
Prognostic Significance of Serum Insulin-Like Growth Factor-1 in Hepatocellular Cancer Patients: A Validation Study.J Hepatocell Carcinoma. 2020 Sep 16;7:143-153. doi: 10.2147/JHC.S258930. eCollection 2020. J Hepatocell Carcinoma. 2020. PMID: 32984091 Free PMC article.
-
Downregulation of Signaling-active IGF-1 by Dipeptidyl Peptidase IV (DPP-IV).Int J Biomed Sci. 2010 Dec;6(4):301-9. Int J Biomed Sci. 2010. PMID: 23675206 Free PMC article.
-
Effects of exercise on inflammatory factors and IGF system in breast cancer survivors: a meta-analysis.BMC Womens Health. 2022 Dec 8;22(1):507. doi: 10.1186/s12905-022-02058-5. BMC Womens Health. 2022. PMID: 36482346 Free PMC article.
-
Alterations in the insulin-like growth factor system during treatment with diethylstilboestrol in patients with metastatic breast cancer.Br J Cancer. 2001 Jul 20;85(2):147-51. doi: 10.1054/bjoc.2001.1871. Br J Cancer. 2001. PMID: 11461068 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous